EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

Wen Sun, Yansha Liu, Hui Dong, Yun Huang

Frontiers in Oncology · 15.06.2026 · 16

DOI: 10.3389/fonc.2026.1849030 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 15.06.2026. Verfasst von Wen Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Yantaishan Hospital, Yantai, Shandong, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrent or metastatic nasopharyngeal carcinoma (RM−NPC) is associated with poor prognosis. PD−1 inhibitors combined with chemotherapy have become the standard first−line treatment, but the comparative efficacy, long−term survival, and safety of different PD−1 inhibitors remain unclear. This study aimed to evaluate the impact of distinct PD−1 inhibitors plus chemotherapy for RM−NPC.

Methods

We conducted a systematic review and single−arm meta−analysis including 19 studies with 1459 patients. Outcomes included objective response rate (ORR), disease control rate (DCR), progression−free survival (PFS), overall survival (OS), and grade ≥3 treatment−related adverse events (TRAEs). Pooled analyses and subgroup comparisons stratified by PD−1 inhibitor type were performed.

Results

The pooled ORR was 64% and DCR was 94% across all regimens. Subgroup analyses stratified by PD−1 inhibitor type revealed significant differences: toripalimab−based regimens achieved the highest ORR and longest median PFS of 21.4 months, while tislelizumab plus chemotherapy yielded the most favorable median OS of 45.3 months. Camrelizumab plus chemotherapy showed a median OS of 34.5 months. Subgroup analysis by study design (randomized controlled trials vs. non−randomized single−arm studies) confirmed highly consistent outcomes, supporting the robustness of pooled estimates. The pooled incidence of grade ≥3 TRAEs was 13%, with comparable safety profiles across all PD−1 inhibitors and no unexpected safety signals.

Conclusions

PD−1 inhibitors combined with chemotherapy provide robust efficacy and durable long−term survival benefits in RM−NPC. Toripalimab, tislelizumab, and camrelizumab demonstrate superior therapeutic effects compared with other agents, with toripalimab showing optimal tumor response and PFS, and tislelizumab offering the best long−term OS. The findings support individualized PD−1 inhibitor selection in clinical practice and confirm the reliability of single−arm meta−analyses combining randomized and non−randomized evidence for agent−stratified comparison. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420261361323.

Schlagwörter

Stichwörter der Autor:innen

PD−1 inhibitorchemotherapyefficacymeta−analysisnasopharyngeal carcinomasurvival

Autor:innen und Institutionen

  • Department of Otolaryngology, Yantaishan Hospital, Yantai, Shandong, China.
  • Department of Otolaryngology, Ganzhou People's Hospital, Ganzhou, Jiang Xi, China.

Zitieren

APA

Sun, W., Liu, Y., Dong, H., & Huang, Y. (2026). Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1849030

Vancouver

Sun W, Liu Y, Dong H, Huang Y. Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1849030

BibTeX
@article{Sun2026,
  author = {Sun, Wen and Liu, Yansha and Dong, Hui and Huang, Yun},
  title = {Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1849030}
}
Kostenlos starten →